• Explore /
  • Poster
  • / A phase Ib/IIa study of DX1002, a novel drug in patients with pretreated advanced hepatocellular carcinoma: Efficacy and safety analysis.

A phase Ib/IIa study of DX1002, a novel drug in patients with pretreated advanced hepatocellular carcinoma: Efficacy and safety analysis.

Abstract Poster

Authors

null

Min Yuan

Shanghai Tenth People’s Hospital, Shanghai, China

Min Yuan , Zhuqing Liu , Xianling Guo , Qing Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

ChiCTR2400080296

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 3122)

DOI

10.1200/JCO.2024.42.16_suppl.3122

Abstract #

3122

Poster Bd #

267

Abstract Disclosures

Similar Posters

First Author: Baojiang Liu

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Efficacy and safety of anlotinib with PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma: A real-world study.

Efficacy and safety of anlotinib with PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma: A real-world study.

First Author: Kehe Chen

First Author: Tawesak Tanwandee

First Author: Panpan Zhang